Skip to Content
Merck
  • Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.

Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.

Nature communications (2019-12-08)
Anastasiia Gusach, Aleksandra Luginina, Egor Marin, Rebecca L Brouillette, Élie Besserer-Offroy, Jean-Michel Longpré, Andrii Ishchenko, Petr Popov, Nilkanth Patel, Taku Fujimoto, Toru Maruyama, Benjamin Stauch, Margarita Ergasheva, Daria Romanovskaia, Anastasiia Stepko, Kirill Kovalev, Mikhail Shevtsov, Valentin Gordeliy, Gye Won Han, Vsevolod Katritch, Valentin Borshchevskiy, Philippe Sarret, Alexey Mishin, Vadim Cherezov
ABSTRACT

Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. While selective inhibition of CysLT1R has been used for treating asthma and associated diseases for over two decades, CysLT2R has recently started to emerge as a potential drug target against atopic asthma, brain injury and central nervous system disorders, as well as several types of cancer. Here, we describe four crystal structures of CysLT2R in complex with three dual CysLT1R/CysLT2R antagonists. The reported structures together with the results of comprehensive mutagenesis and computer modeling studies shed light on molecular determinants of CysLTR ligand selectivity and specific effects of disease-related single nucleotide variants.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholesteryl hemisuccinate tris salt, anionic detergent
Sigma-Aldrich
Cholesteryl hemisuccinate
Avanti
n-dodecyl-β-D-maltoside (DDM), Avanti Research - A Croda Brand